OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
December 22, 2014
FDA set several milestones in approving more new, important drugs and biologics in 2014. Breakthrough drug designations went through through the roof, speeding more new therapies for cancer and critical conditions to patients.
December 19, 2014
FDA has scheduled a public meeting in early January to assess and weigh data on the first United States application for a biosimilar therapy.
December 16, 2014
Patient access to critical experimental medicines continues to grab public attention as states enact “Right-to-Try” laws and Congress eyes establishing a national policy to provide not-yet-approved therapies to terminally ill patients.
December 15, 2014
The development and approval of new vaccines and antivirals to contain and treat the Ebola virus outbreak has become a top priority for the federal government and Congress, as seen in new policies to spur R&D and added funding for these efforts.
December 04, 2014
Spending rises on prescription drugs despite overall slow-down in health care outlays.
December 02, 2014
Operational changes at FDA and CDER aim to improve global market monitoring.